Consistent with the reports discussed above, AST treatment decreased the expression levels of eotaxin, MIF, HDC and Th2-type cytokines, including IL-4 and IL-5, in a murine model of AD and protected against the development of AD symptoms by inhibiting the production of inflammatory cytokines in this study. This evidence concerns the gene MIF and Alzheimer disease.